Der Chirurg

, Volume 83, Issue 1, pp 38–44 | Cite as

Neu erkannte Nebenwirkungen von Protonenpumpeninhibitoren

Argumente Pro Fundoplicatio bei GERD?
  • B.H.A. von Rahden
  • M. Scheurlen
  • J. Filser
  • H.J. Stein
  • C.-T. Germer
Übersichten

Zusammenfassung

Protonenpumpeninhibitoren (PPI) werden unter anderem zur medikamentösen Therapie der gastroösophagealen Refluxkrankheit (GERD) verwendet. PPI sind die meistverschriebenen und -verwendeten Medikament in der Gastroenterologie. PPI wurden bislang als sehr nebenwirkungsarm angesehen. In den letzten Jahren häufen sich allerdings Studienergebnisse zu neuen relevanten Nebenwirkungen. Wir liefern einen Überblick zur aktuellen Datenlage der PPI-Nebenwirkungen und diskutieren deren Relevanz für die Therapieverfahrenswahl bei GERD (medikamentöse Dauertherapie vs. Antirefluxchirurgie).

PPI sind nach neuen Daten assoziiert mit: osteoporosebedingten Frakturen, Clostridium-difficile-assoziierter Diarrhö (CDAD), nosokomialen und extranosokomialen Pneumonien, pharmakologischer Interaktion mit Clopidogrel und Acetylsalicylsäure und konsekutiv vermehrten kardiovaskulären Ereignissen, therapierefraktärer Hypomagnesiämie, Rebound-Refluxsymptomen etc. Die Nutzen-Risiko-Relation bei den PPIs sollte zunehmend kritischer beurteilt werden, da – insbesondere bei Langzeiteinnahme – die Nebenwirkungen die positiven Effekte überwiegen können. Die schweren PPI-Nebenwirkungen können als starkes Argument zugunsten der laparoskopischen Fundoplicatio bei GERD gelten.

Schlüsselwörter

Gastroenterologie Protonenpumpeninhibitoren Nebenwirkungen Gastroösophageale Refluxkrankheit Fundoplicatio 

Newly recognized side-effects of proton pump inhibitors

Arguments in favour of fundoplication for GERD?

Abstract

Among other indications proton pump inhibitors (PPIs) are used as medical treatment of gastroesophageal reflux disease (GERD) and are the most frequently prescribed and most frequently used drugs in gastroenterology. Until recently PPIs were regarded as very safe and associated with very few side-effects. However, during recent years study results have revealed many severe adverse events associated especially with long-term PPI use. We review the currently available evidence, regarding the side-effects of PPIs and discuss the potential impact on treatment strategies for GERD (conservative treatment vs. antireflux surgery).

Currently available data suggest that PPIs are associated with osteoporosis-related fractures, Clostridium difficile associated diarrhea (CDAD), community and hospital-acquired pneumonia, pharmacologic interaction with clopidogrel and acetylsalicylic acid with subsequent increased rate of cardiovascular events, refractory hypomagnesemia and rebound reflux symptoms etc. The risk-benefit ratio of PPIs is increasingly recognized as being less favourable. This leads to a more critical viewpoint and raises the question whether the side-effects of PPIs may outweigh the benefits, especially with long-term use. The side-effects of PPIs seem to make a strong argument in favour of laparoscopic fundoplication in the treatment of GERD.

Keywords

Gastroenterology Proton pump inhibitors Side-effects Gastroesophageal reflux disease Fundoplication 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Andrès E, Noel E, Abdelghani MB (2003) Vitamin B(12) deficiency associated with chronic acid suppression therapy. Ann Pharmacother 37:1730PubMedCrossRefGoogle Scholar
  2. 2.
    Aseeri M, Schroeder T, Kramer J, Zackula R (2008) Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 103:2308–2313PubMedCrossRefGoogle Scholar
  3. 3.
    Bhatt DL, Cryer BL, Contant CF et al (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363:1909–1917PubMedCrossRefGoogle Scholar
  4. 4.
    Broeren MA, Geerdink EA, Vader HL, Wall Bake AW van den (2009) Hypomagnesium induced by several proton-pump inhibitors. Ann Intern Med 151:755–756PubMedGoogle Scholar
  5. 5.
    Charlot M, Ahlehoff O, Norgaard ML et al (2010) Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 153:378–386PubMedGoogle Scholar
  6. 6.
    Charlot M, Grove EL, Hansen PR et al (2011) Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 342:d2690. DOI 10.1136/bmj.d2690PubMedCrossRefGoogle Scholar
  7. 7.
    Collet JP, Hulot JS, Pena A et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with Clopidogrel after myocardial infarction: a cohort study. Lancet 373:309–317PubMedCrossRefGoogle Scholar
  8. 8.
    Das D, Chilton AP, Jankowski JA (2009) Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 181:161–169PubMedCrossRefGoogle Scholar
  9. 9.
    Dial S, Alrasadi K, Manoukian C et al (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171:33–38PubMedCrossRefGoogle Scholar
  10. 10.
    Dial S, Delaney JA, Barkun AN, Suissa S (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294:2989–2995PubMedCrossRefGoogle Scholar
  11. 11.
    Epstein M, McGrath S, Law F (2006) Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 17:1834–1836CrossRefGoogle Scholar
  12. 12.
    European Medicines Agency (2009) Public statement on possible interaction between clopidogrel and proton pump inhibitors. www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500014409.pdfGoogle Scholar
  13. 13.
    FDA Drug Safety Communication. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). www.fda.gov/Drugs/DrugSafety/ucm079520.htmGoogle Scholar
  14. 14.
    FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). www.fda.gov/Drugs/DrugSafety/ucm245011.htmGoogle Scholar
  15. 15.
    FDA Drug Safety Communication (2009) Plavix (clopidogrel bisulfate) 75 mg tablets. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). www.fda.gov/Safety/MedWatch/SafetyInformation/ucm165166.htmGoogle Scholar
  16. 16.
    Fiocca R, Mastracci L, Engström C et al (2010) Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am J Gastroenterol 105:1015–1023PubMedCrossRefGoogle Scholar
  17. 17.
    Fossmark R, Johnsen G, Johanessen E, Waldum HL (2005) Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 21:149–154PubMedCrossRefGoogle Scholar
  18. 18.
    Galmiche JP, Hatlebakk J, Attwood S et al (2011) Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial. JAMA 305:1969–1677PubMedCrossRefGoogle Scholar
  19. 19.
    Georgopoulos SD, Polymeros D, Triantafyllou K et al (2006) Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion 74:42–46PubMedCrossRefGoogle Scholar
  20. 20.
    Gillen D, Wirz AA, Ardill JE, McColl KE (1999) Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116:239–247PubMedCrossRefGoogle Scholar
  21. 21.
    Gray SL, LaCroix AZ, Larson J et al (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 170:765–771PubMedCrossRefGoogle Scholar
  22. 22.
    Härmark L, Wiel HE van der, Groot MC de, Grootheest AC van (2007) Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 64:819–823PubMedGoogle Scholar
  23. 23.
    Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (2009) Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 301:2120–2128PubMedCrossRefGoogle Scholar
  24. 24.
    Ho PM, Maddox TM, Wang L et al (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937–944PubMedCrossRefGoogle Scholar
  25. 25.
    Howell MD, Novack V, Grgurich P et al (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170:784–790PubMedCrossRefGoogle Scholar
  26. 26.
    Islami F, Kamangar F, Boffetta P (2009) Use of proton pump inhibitors and risk of progression of Barrett’s esophagus to neoplastic lesions. Am J Gastroenterol 104:2646–2648PubMedCrossRefGoogle Scholar
  27. 27.
    Katz MH (2010) Failing the acid test: Benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 170:747–748PubMedCrossRefGoogle Scholar
  28. 28.
    Klinkenberg-Knol EC, Nelis F, Dent J et al (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118:661–669PubMedCrossRefGoogle Scholar
  29. 29.
    Koop H, Schepp W, Müller-Lissner S et al (2005) Gastroösophageale Refluxkrankheit – Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol 43:163–164PubMedCrossRefGoogle Scholar
  30. 30.
    Kwok CS, Yeong JK, Loke YK (2011) Meta-analysis: risk of fractures with acid-suppressing medication. Bone 48:768–776PubMedCrossRefGoogle Scholar
  31. 31.
    Laheij RJ, Sturkenboom MC, Hassing RJ et al (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292:1955–1960PubMedCrossRefGoogle Scholar
  32. 32.
    Laine L, Hennekens C (2010) Proton pump inhibitor and clopidogrel interaction: Fact or fiction? Am J Gastroenterol 105:34–41PubMedCrossRefGoogle Scholar
  33. 33.
    McColl KE, Gillen D (2009) Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology 137:20–22PubMedCrossRefGoogle Scholar
  34. 34.
    Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362PubMedCrossRefGoogle Scholar
  35. 35.
    Miano TA, Reichert MG, Houle TT et al (2009) Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. Chest 136:440–447PubMedCrossRefGoogle Scholar
  36. 36.
    Ngamruengphong S, Leontiadis GI, Radhi S et al (2011) Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol [Epub ahead of print]Google Scholar
  37. 37.
    Nguyen DM, El-Serag HB, Henderson L et al (2009) Medication usage and the risk of neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 7:1299–1304PubMedCrossRefGoogle Scholar
  38. 38.
    Ray S, Delaney M, Muller AF (2010) Proton pump inhibitors and acute interstitial nephritis. BMJ 341:c4412. DOI 10.1136/bmj.c4412PubMedCrossRefGoogle Scholar
  39. 39.
    Reimer C, Søndergaard B, Hilsted L, Bytzer P (2009) Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 137:80–87PubMedCrossRefGoogle Scholar
  40. 40.
    Robertson DJ, Larsson H, Friis S et al (2007) Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 133:755–760PubMedCrossRefGoogle Scholar
  41. 41.
    Sarkar M, Hennessy S, Yang YX (2008) Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 149:391–398PubMedGoogle Scholar
  42. 42.
    Shabajee N, Lamb E, Sturgess I, Sumathipala R (2008) Omeprazole and refractory hypomagnesemia. BMJ 337:173–175CrossRefGoogle Scholar
  43. 43.
    Sierra F, Suarez M, Rey M, Vela MF (2007) Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 26:545–553PubMedCrossRefGoogle Scholar
  44. 44.
    Simpson IJ, Marshall MR, Pilmore H et al (2006) Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology 11:381–385PubMedCrossRefGoogle Scholar
  45. 45.
    Smeets HM, Hoes AW, Wit NJ de (2007) Effectiveness and costs of implementation strategies to reduce acid suppressive drug prescriptions: a systematic review. BMC Health Serv Res 7:177PubMedCrossRefGoogle Scholar
  46. 46.
    Southern WN, Rahmani R, Aroniadis O et al (2010) Postoperative Clostridium difficile-associated diarrhea. Surgery 148:24–30PubMedCrossRefGoogle Scholar
  47. 47.
    Targownik LE, Leslie WD (2011) The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf (Epub ahead of print)Google Scholar
  48. 48.
    Teichert M, Noord C van, Uitterlinden AG et al (2011) Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol 153:379–385PubMedCrossRefGoogle Scholar
  49. 49.
    Soest EM van, Rossum LG van, Dieleman JP et al (2008) Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 103:966–973PubMedCrossRefGoogle Scholar
  50. 50.
    Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83PubMedCrossRefGoogle Scholar
  51. 51.
    Rahden BHA von, Filser J, Germer CT (2011) PPI vs. Fundoplicatio in der Behandlung der gastroösophagealen Refluxkrankheit: Ergebnisse der Cochrane-Metaanalyse und der LOTUS-Studie. Chirurg (im Druck)Google Scholar
  52. 52.
    Wileman SM, McCann S, Grant AM et al (2010) Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev CD003243Google Scholar
  53. 53.
    Yang YX, Hennessy S, Propert K et al (2007) Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133:748–754PubMedCrossRefGoogle Scholar
  54. 54.
    Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953PubMedCrossRefGoogle Scholar
  55. 55.
    Yang YX, Metz DC (2010) Safety of proton pump inhibitor exposure. Gastroenterology 139:1115–1127PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • B.H.A. von Rahden
    • 1
  • M. Scheurlen
    • 2
  • J. Filser
    • 1
  • H.J. Stein
    • 3
  • C.-T. Germer
    • 1
  1. 1.Klinik für Allgemein-, Viszeral-, Gefäß und Kinderchirurgie, Zentrum für operative Medizin (ZOM)Universitätsklinikum WürzburgWürzburgDeutschland
  2. 2.II. Medizinische Klinik, Abteilung für GastroenterologieUniversitätsklinikum WürzburgWürzburgDeutschland
  3. 3.Klinik für Allgemein-, Viszeral- und ThoraxchirurgieKlinikum Nürnberg NordNürnbergDeutschland

Personalised recommendations